Cytomegalovirus infection as a possible protective factor for multiple sclerosis
Article Sidebar
Main Article Content
Abstract
Objective: To understand whether there is an association of cytomegalovirus infection and whether it may be a relevant protective factor in the risk of multiple sclerosis. Methods: This is an integrative review that explored scientific productions disseminated in journals in databases of the United States National Library of Medicine (PubMed), VHL and Cochrane; inclusion and exclusion criteria were applied for the analysis of results and discussion. Descriptors used were: “cytomegalovirus”, “multiple sclerosis”, “patients” using the Boolean operator “and”. Results: This study analyzed 21 studies in order to understand whether there is an association and the role of CMV in the etiology of MS. The results were presented in Table 1, providing information on the authors, year of publication, objective, and main conclusions. Finals considerations: It is evident the need for further research to prove the association of cytomegalovirus infection as a possible protective factor for MS.
Article Details
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
References
2. AUER M, et al. Correlation between anti-JC-virus and anti-cytomegalovirus, Epstein-Barr virus and –measles/rubella/varicella-zoster virus antibodies. 2017; 89(1): 3-9.
3. CLIFF JC. Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). 2019; 10: 796.
4. EFTHYMIOU G, et al. A compreensive analysis of antigen-specific antibody responses against human cytomegalovirus in patients with systemic scleroisis. Clin Immunol; 2019; 207: 87-96.
5. FROHMAN, E. et al., Multiple Sclerosis - The Plaque and the pathogenesis. N Engl J Med., [S.l.], 2006; 354: 942-55.
6. GRUT VM. Cytomegalovirus seropositivity is associated with reduced risk of multiple scleroise –a presymptomatic case-control study. Eur J. Neurol; 2021; 28(9): 3072-3079.
7. HALENIUS A, et al. Human cytomegalovirus and autoimmune disease. Biomed Res. Int; 2014; 472978.
8. HORAKOVA DJ, et al. Environmental factors associed with disease progression after the first demylinating event: results from the multi-center SET study. PloS One; 2013; 8(1): e 53996.
9. KARAMPOOR S, et al. Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple scleroises: A population based study. J Neuroimmunol; 2017; 309: 4-6.
10. KUHLER J, et al. Conversion from clinically isolated syndrome to multiple scleroise: A large multicentre study. MultScler; 2015; 21(8): 1013-24.
11. MAKHANI NS, et al. Viral exposures and MS outcome in a prospective cohort of children with acquired de myelination. Multscler; 2016; 22(3): 385-8.
12. MAROU E, et al. Human Cytomegalovirus (HCMV) UL44 and UL57 specific antibody responses in anti-HCMV positive with systemic scleroises. ClinRheumtol; 2017; 36(4): 863-869.
13. MARTÍNES-RODRÍGUEZ J, et al. Adaptive natural killer cell responses to cytomegalovirus and disability progression in multiple scleroises. MultScler; 2016; 22(6): 741-52.
14. MOREIRA A, et al. Características adaptativas das células natural Killer na esclerose múltipla. Front Immunol; 2019; 10:2403.
15. MUNGER K, et al. Epstein-Barr and multiple sclerosis risk in the finnish maternity cohort. Ann Neurol; 2019; 86(3): 436-442.
16. NAJAFI S, et al. Prevalence of cytomegalovirus in patients with multiple sclerosis: A case-control study in Northern Iran. Jundishapur J Microbiol; 2016; 9(7): e36582.
17. SADAM H, et al. Identification of two highly antigenic epitope markes predicting multiple sclerosis in optic neuritis patients. EBioMEDICINE; 2021; 64:103211.
18. SALIM M, et al. Determining the IgM and IgG antibody titer against CMV and helicobacter pylori in the serum of multiple sclerosis patients comparing to the control group in Hamadan. Hum Antibodies; 2017; 26(1):23-28.
19. SUNDQVIST ET, et al. Cytomegalovirus seropositivity is negatively associed with multiple sclerosis. MultScle; 2014; 20(2): 165-73.
20. THAKOLWIBOON S, et al. Regional differences in the association of cytomegalovirus seropositivity and multiplr sclerosis: A systematic review and meta-analysis. MultScler Relat Disord; 2020; 45: 102393.
21. YUAN S, et al. An atlas on risk factors for multiple sclerosis: a mendelian randomization study. J Neurol., 2021; 268(1): 114-124.
22. ZAPPULO E, et al. Incidence and Predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CS20 and CD52 surface antigens. Open Forum Infect Dis; 2019; 6(11): ofz444.